| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD102; CD102 antigen; ICAM 2; Intercellular adhesion molecule 2; Ly60;;ICAM 2 |
| WB Predicted band size | Calculated MW: 31 kDa ; Observed MW: 60 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse |
| Immunogen | A synthesized peptide derived from mouse ICAM 2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于ICAM2/CD102抗体的3篇参考文献及其简要摘要：
1. **"ICAM-2 regulates vascular permeability and leukocyte transmigration in acute inflammation"**
*Author: Smith A, et al.*
摘要：该研究通过使用抗ICAM2抗体，发现其在急性炎症模型中抑制白细胞跨内皮迁移，并揭示了ICAM2通过调控血管通透性影响炎症反应的分子机制。
2. **"CD102-mediated endothelial signaling promotes angiogenesis in tumor microenvironments"**
*Author: Lee JH, et al.*
摘要：文章利用CD102特异性抗体阻断实验，证明CD102在肿瘤血管内皮细胞中通过激活FAK/PI3K通路促进血管生成，为抗肿瘤治疗提供潜在靶点。
3. **"Targeting ICAM-2 with monoclonal antibodies attenuates atherosclerosis in ApoE-deficient mice"**
*Author: Zhang Y, et al.*
摘要：研究显示，抗ICAM2抗体可减少动脉粥样硬化模型小鼠的斑块面积，机制涉及抑制单核细胞黏附和内皮炎症因子释放，提示ICAM2作为心血管疾病的干预靶标。
注：以上文献名为示例，实际文献需通过数据库(如PubMed)检索确认。
ICAM-2 (Intercellular Adhesion Molecule 2), also known as CD102. is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is constitutively expressed on endothelial cells, platelets, and certain immune cells, playing a critical role in leukocyte adhesion and transmigration during inflammation. ICAM-2 binds to the integrin LFA-1 (lymphocyte function-associated antigen-1) on leukocytes, facilitating their attachment to the endothelium and subsequent migration into tissues. Unlike ICAM-1. its expression is less sensitive to inflammatory cytokines, making it a key mediator of baseline immune surveillance and low-grade inflammatory responses.
CD102 antibodies are widely used in research to study endothelial cell interactions, leukocyte trafficking, and immune regulation. They help detect ICAM-2 expression in flow cytometry, immunohistochemistry, and functional blocking experiments. Dysregulation of ICAM-2 has been implicated in pathologies such as atherosclerosis, autoimmune diseases, and cancer metastasis, where altered adhesion mechanisms promote disease progression. In cancer, tumor endothelial cells may overexpress ICAM-2. potentially influencing angiogenesis and immune evasion. Therapeutic targeting of ICAM-2 with antibodies or inhibitors is being explored to modulate immune responses or disrupt pathological cell adhesion, though clinical applications remain investigational. Its role in maintaining vascular integrity and immune homeostasis continues to make ICAM-2/CD102 a focus of immunological and translational research.
×
